Celgene Corp (CELG) 119.57 $CELG Celgene's (CEL
Post# of 64074
Posted On: 03/04/2015 6:02:47 PM
Celgene Corp (CELG) 119.57 $CELG
Celgene's (CELG) Management Presents at Cowen and Company 35th Annual Health Care Conference - Conference Call Transcript
SA Transcripts - at Seeking Alpha - 1 hr 39 mins ago
CELG: 119.57 (+1.10)
Midday Glance: Biotechnology companies
AP - Wed Mar 04, 12:16PM CST
NEW YORK (AP) — Shares of some top biotechnology companies are up at 1 p.m.:
GILD: 103.06 (+0.27), AMGN: 159.19 (+0.63), CELG: 119.57 (+1.10)
Biotech Stock Roundup: Orexigen Soars on Contrave Data, Amgen Scores in Study - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Mar 04, 10:35AM CST
Orexigen (OREX) soars on news regrading obesity drug, Contrave. Amgen's (AMGN) multiple myeloma drug, Kyprolis, is better than Velcade in a head-to-head study.
OREX: 8.49 (+0.85), VRTX: 120.05 (-3.47), ISIS: 70.16 (+1.50), GILD: 103.06 (+0.27), AMGN: 159.19 (+0.63), ARNA: 4.32 (+0.28), CELG: 119.57 (+1.10)
Early Glance: Biotechnology companies
AP - Wed Mar 04, 9:36AM CST
NEW YORK (AP) — Shares of some top biotechnology companies are down at 10 a.m.:
GILD: 103.06 (+0.27), AMGN: 159.19 (+0.63), CELG: 119.57 (+1.10)
Amgen Still In Play With Endeavor To Expand Kyprolis
EP Vantage - Seeking Alpha - Wed Mar 04, 9:10AM CST
A mgen (NASDAQ: AMGN ) had already made strides to boost Kyprolis ’s relevance in the multiple myeloma market, and the most important aspect of yesterday’s interim analysis of the Endeavor study is that it allays the worst fears about...
AMGN: 159.19 (+0.63), CELG: 119.57 (+1.10)
Pioneer Fundamental Growth Fund: Why Is It Revving Up?
at Investor's Business Daily - Tue Mar 03, 5:50PM CST
Stock mutual fund managers Andrew Acheson and Paul Cloonan have been kicking it into a higher gear at Pioneer Fundamental Growth Fund. The 16.61% average annual return of their $2.4 billion fund ranked in the top 27% of its large-cap growth rivals...
SBUX: 93.06 (-0.94), ESRX: 84.83 (+0.48), LNKD: 265.23 (-0.31), GILD: 103.06 (+0.27), ABBV: 60.27 (+0.65), AAPL: 128.54 (-0.82), CELG: 119.57 (+1.10)
Celgene's Abraxane Combination Therapy Cleared in the EU - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Mar 03, 5:33PM CST
Celgene Corporation's (CELG) Abraxane was approved in the EU in combination with carboplatin for the first-line treatment of NSCLC
CYTK: 7.95 (-0.02), LLY: 70.65 (+0.28), AFFX: 11.83 (+0.09), CELG: 119.57 (+1.10)
Final Glance: Biotechnology companies
AP - Tue Mar 03, 5:05PM CST
NEW YORK (AP) — Shares of some top biotechnology companies were down at the close of trading:
GILD: 103.06 (+0.27), AMGN: 159.19 (+0.63), CELG: 119.57 (+1.10)
Amgen: The Best Biotech Stock You Don't Own
Dan Strack - at Seeking Alpha - Tue Mar 03, 4:04PM CST
BIIB: 414.13 (+1.34), GILD: 103.06 (+0.27), PFE: 34.64 (+0.08), MRK: 57.88 (-0.46), AMGN: 159.19 (+0.63), ABBV: 60.27 (+0.65), GSK: 47.82 (+0.11), BMY: 65.67 (+3.75), HSP: 87.95 (+0.24), NVS: 99.04 (-0.02), CELG: 119.57 (+1.10)
Stock Markets Take a Breather After Monday's Record Run
at The Street - Tue Mar 03, 3:11PM CST
Stocks took a break from smashing records and hitting multi-year highs on Tuesday.
BCS: 16.03 (+0.37), PSX: 77.96 (-0.13), F: 16.03 (-0.14), DKS: 55.98 (-0.02), PFE: 34.64 (+0.08), C: 53.67 (-0.06), MYL: 55.60 (+0.16), BBY: 39.79 (+0.61), COP: 64.25 (-0.53), LL: 35.64 (-5.14), XLV: 72.58 (+0.35), CELG: 119.57 (+1.10), AZO: 652.48 (+0.58), TOT: 52.82 (-0.27), GILD: 103.06 (+0.27), TGT: 77.72 (-0.28), LEAF: 49.91 (-0.32), GM: 37.57 (-0.23), BP: 41.53 (-0.21), XLE: 78.65 (-0.11), BABA: 85.49 (+3.91)
Stocks Recover From Lows After Crude Oil Jumps Over $50
at The Street - Tue Mar 03, 2:22PM CST
Stocks move off session lows by mid-afternoon Tuesday, buoyed by a rally in oil prices.
BCS: 16.03 (+0.37), F: 16.03 (-0.14), GE: 25.66 (-0.20), DKS: 55.98 (-0.02), PFE: 34.64 (+0.08), C: 53.67 (-0.06), MYL: 55.60 (+0.16), BBY: 39.79 (+0.61), LL: 35.64 (-5.14), XLV: 72.58 (+0.35), CELG: 119.57 (+1.10), AZO: 652.48 (+0.58), GILD: 103.06 (+0.27), GM: 37.57 (-0.23), LEAF: 49.91 (-0.32), BABA: 85.49 (+3.91)
Nasdaq Hits 5000: 3 Choices to Ride the Upswing - Analyst Blog
Swarup Gupta - Zacks Investment Research - Tue Mar 03, 10:36AM CST
Echoes of the dot-com boom could be heard yesterday after the Nasdaq closed above 5,000 for the first time in 15 years.
AMZN: 382.72 (-1.89), BIIB: 414.13 (+1.34), FB: 80.89 (+1.29), AMGN: 159.19 (+0.63), H: 60.77 (-0.49), INTC: 34.12 (+0.02), PCLN: 1,225.67 (-16.36), CELG: 119.57 (+1.10), SBUX: 93.06 (-0.94), GILD: 103.06 (+0.27), MSFT: 43.06 (-0.22), AAPL: 128.54 (-0.82), CSCO: 29.33 (-0.21), ONNN: 13.02 (+0.15)
Stocks Slip From Highs; Mylan Pulls Health Care Sector Lower
at The Street - Tue Mar 03, 10:28AM CST
Stocks fall back from records on Tuesday morning.
BCS: 16.03 (+0.37), MDR: 3.43 (+0.10), F: 16.03 (-0.14), GE: 25.66 (-0.20), DKS: 55.98 (-0.02), PFE: 34.64 (+0.08), C: 53.67 (-0.06), MYL: 55.60 (+0.16), BBY: 39.79 (+0.61), LL: 35.64 (-5.14), CELG: 119.57 (+1.10), AZO: 652.48 (+0.58), GILD: 103.06 (+0.27), GM: 37.57 (-0.23), LEAF: 49.91 (-0.32)
Ligand Pharmaceuticals Weakens The Bear Case
Trevor Lowenthal - at Seeking Alpha - Tue Mar 03, 10:17AM CST
LGND: 67.55 (+1.10), AMGN: 159.19 (+0.63), CELG: 119.57 (+1.10)
Abraxane expanded label cleared in Europe
Seeking Alpha - at Seeking Alpha - Mon Mar 02, 9:47AM CST
CELG: 119.57 (+1.10)
Investors Are Best To Avoid The IShares Nasdaq Biotechnology ETF
Investing Healthcare - at Seeking Alpha - Mon Mar 02, 9:24AM CST
JNJ: 101.65 (-0.69), BIIB: 414.13 (+1.34), ACAD: 38.14 (unch), SPY: 210.23 (-0.89), PCYC: 230.48 (+13.72), GILD: 103.06 (+0.27), MRK: 57.88 (-0.46), ALXN: 182.53 (+0.02), IBB: 340.09 (+2.17), CELG: 119.57 (+1.10)
ABRAXANE(R) Approved by European Commission for First-Line Treatment of Patients with Non-Small Cell Lung Cancer
Business Wire - Mon Mar 02, 8:45AM CST
Celgene International Sarl, a wholly owned subsidiary of Celgene Corporation (NASDAQ: CELG), today announced that the European Commission (EC) has approved ABRAXANE(R) (paclitaxel formulated as albumin-bound nanoparticles, or nab-paclitaxel) in combination with carboplatin for the first-line treatment of non-small cell lung cancer in adult patients who are not candidates for potentially curative surgery and/or radiation therapy.
CELG: 119.57 (+1.10), CELGZ: 3.24 (+0.01)
Amgen's Long Case Strengthens After Kyprolis Data
Investing Healthcare - at Seeking Alpha - Mon Mar 02, 7:41AM CST
AMGN: 159.19 (+0.63), CELG: 119.57 (+1.10)
Celgene's (CELG) Management Presents at Cowen and Company 35th Annual Health Care Conference - Conference Call Transcript
SA Transcripts - at Seeking Alpha - 1 hr 39 mins ago
CELG: 119.57 (+1.10)
Midday Glance: Biotechnology companies
AP - Wed Mar 04, 12:16PM CST
NEW YORK (AP) — Shares of some top biotechnology companies are up at 1 p.m.:
GILD: 103.06 (+0.27), AMGN: 159.19 (+0.63), CELG: 119.57 (+1.10)
Biotech Stock Roundup: Orexigen Soars on Contrave Data, Amgen Scores in Study - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Mar 04, 10:35AM CST
Orexigen (OREX) soars on news regrading obesity drug, Contrave. Amgen's (AMGN) multiple myeloma drug, Kyprolis, is better than Velcade in a head-to-head study.
OREX: 8.49 (+0.85), VRTX: 120.05 (-3.47), ISIS: 70.16 (+1.50), GILD: 103.06 (+0.27), AMGN: 159.19 (+0.63), ARNA: 4.32 (+0.28), CELG: 119.57 (+1.10)
Early Glance: Biotechnology companies
AP - Wed Mar 04, 9:36AM CST
NEW YORK (AP) — Shares of some top biotechnology companies are down at 10 a.m.:
GILD: 103.06 (+0.27), AMGN: 159.19 (+0.63), CELG: 119.57 (+1.10)
Amgen Still In Play With Endeavor To Expand Kyprolis
EP Vantage - Seeking Alpha - Wed Mar 04, 9:10AM CST
A mgen (NASDAQ: AMGN ) had already made strides to boost Kyprolis ’s relevance in the multiple myeloma market, and the most important aspect of yesterday’s interim analysis of the Endeavor study is that it allays the worst fears about...
AMGN: 159.19 (+0.63), CELG: 119.57 (+1.10)
Pioneer Fundamental Growth Fund: Why Is It Revving Up?
at Investor's Business Daily - Tue Mar 03, 5:50PM CST
Stock mutual fund managers Andrew Acheson and Paul Cloonan have been kicking it into a higher gear at Pioneer Fundamental Growth Fund. The 16.61% average annual return of their $2.4 billion fund ranked in the top 27% of its large-cap growth rivals...
SBUX: 93.06 (-0.94), ESRX: 84.83 (+0.48), LNKD: 265.23 (-0.31), GILD: 103.06 (+0.27), ABBV: 60.27 (+0.65), AAPL: 128.54 (-0.82), CELG: 119.57 (+1.10)
Celgene's Abraxane Combination Therapy Cleared in the EU - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Mar 03, 5:33PM CST
Celgene Corporation's (CELG) Abraxane was approved in the EU in combination with carboplatin for the first-line treatment of NSCLC
CYTK: 7.95 (-0.02), LLY: 70.65 (+0.28), AFFX: 11.83 (+0.09), CELG: 119.57 (+1.10)
Final Glance: Biotechnology companies
AP - Tue Mar 03, 5:05PM CST
NEW YORK (AP) — Shares of some top biotechnology companies were down at the close of trading:
GILD: 103.06 (+0.27), AMGN: 159.19 (+0.63), CELG: 119.57 (+1.10)
Amgen: The Best Biotech Stock You Don't Own
Dan Strack - at Seeking Alpha - Tue Mar 03, 4:04PM CST
BIIB: 414.13 (+1.34), GILD: 103.06 (+0.27), PFE: 34.64 (+0.08), MRK: 57.88 (-0.46), AMGN: 159.19 (+0.63), ABBV: 60.27 (+0.65), GSK: 47.82 (+0.11), BMY: 65.67 (+3.75), HSP: 87.95 (+0.24), NVS: 99.04 (-0.02), CELG: 119.57 (+1.10)
Stock Markets Take a Breather After Monday's Record Run
at The Street - Tue Mar 03, 3:11PM CST
Stocks took a break from smashing records and hitting multi-year highs on Tuesday.
BCS: 16.03 (+0.37), PSX: 77.96 (-0.13), F: 16.03 (-0.14), DKS: 55.98 (-0.02), PFE: 34.64 (+0.08), C: 53.67 (-0.06), MYL: 55.60 (+0.16), BBY: 39.79 (+0.61), COP: 64.25 (-0.53), LL: 35.64 (-5.14), XLV: 72.58 (+0.35), CELG: 119.57 (+1.10), AZO: 652.48 (+0.58), TOT: 52.82 (-0.27), GILD: 103.06 (+0.27), TGT: 77.72 (-0.28), LEAF: 49.91 (-0.32), GM: 37.57 (-0.23), BP: 41.53 (-0.21), XLE: 78.65 (-0.11), BABA: 85.49 (+3.91)
Stocks Recover From Lows After Crude Oil Jumps Over $50
at The Street - Tue Mar 03, 2:22PM CST
Stocks move off session lows by mid-afternoon Tuesday, buoyed by a rally in oil prices.
BCS: 16.03 (+0.37), F: 16.03 (-0.14), GE: 25.66 (-0.20), DKS: 55.98 (-0.02), PFE: 34.64 (+0.08), C: 53.67 (-0.06), MYL: 55.60 (+0.16), BBY: 39.79 (+0.61), LL: 35.64 (-5.14), XLV: 72.58 (+0.35), CELG: 119.57 (+1.10), AZO: 652.48 (+0.58), GILD: 103.06 (+0.27), GM: 37.57 (-0.23), LEAF: 49.91 (-0.32), BABA: 85.49 (+3.91)
Nasdaq Hits 5000: 3 Choices to Ride the Upswing - Analyst Blog
Swarup Gupta - Zacks Investment Research - Tue Mar 03, 10:36AM CST
Echoes of the dot-com boom could be heard yesterday after the Nasdaq closed above 5,000 for the first time in 15 years.
AMZN: 382.72 (-1.89), BIIB: 414.13 (+1.34), FB: 80.89 (+1.29), AMGN: 159.19 (+0.63), H: 60.77 (-0.49), INTC: 34.12 (+0.02), PCLN: 1,225.67 (-16.36), CELG: 119.57 (+1.10), SBUX: 93.06 (-0.94), GILD: 103.06 (+0.27), MSFT: 43.06 (-0.22), AAPL: 128.54 (-0.82), CSCO: 29.33 (-0.21), ONNN: 13.02 (+0.15)
Stocks Slip From Highs; Mylan Pulls Health Care Sector Lower
at The Street - Tue Mar 03, 10:28AM CST
Stocks fall back from records on Tuesday morning.
BCS: 16.03 (+0.37), MDR: 3.43 (+0.10), F: 16.03 (-0.14), GE: 25.66 (-0.20), DKS: 55.98 (-0.02), PFE: 34.64 (+0.08), C: 53.67 (-0.06), MYL: 55.60 (+0.16), BBY: 39.79 (+0.61), LL: 35.64 (-5.14), CELG: 119.57 (+1.10), AZO: 652.48 (+0.58), GILD: 103.06 (+0.27), GM: 37.57 (-0.23), LEAF: 49.91 (-0.32)
Ligand Pharmaceuticals Weakens The Bear Case
Trevor Lowenthal - at Seeking Alpha - Tue Mar 03, 10:17AM CST
LGND: 67.55 (+1.10), AMGN: 159.19 (+0.63), CELG: 119.57 (+1.10)
Abraxane expanded label cleared in Europe
Seeking Alpha - at Seeking Alpha - Mon Mar 02, 9:47AM CST
CELG: 119.57 (+1.10)
Investors Are Best To Avoid The IShares Nasdaq Biotechnology ETF
Investing Healthcare - at Seeking Alpha - Mon Mar 02, 9:24AM CST
JNJ: 101.65 (-0.69), BIIB: 414.13 (+1.34), ACAD: 38.14 (unch), SPY: 210.23 (-0.89), PCYC: 230.48 (+13.72), GILD: 103.06 (+0.27), MRK: 57.88 (-0.46), ALXN: 182.53 (+0.02), IBB: 340.09 (+2.17), CELG: 119.57 (+1.10)
ABRAXANE(R) Approved by European Commission for First-Line Treatment of Patients with Non-Small Cell Lung Cancer
Business Wire - Mon Mar 02, 8:45AM CST
Celgene International Sarl, a wholly owned subsidiary of Celgene Corporation (NASDAQ: CELG), today announced that the European Commission (EC) has approved ABRAXANE(R) (paclitaxel formulated as albumin-bound nanoparticles, or nab-paclitaxel) in combination with carboplatin for the first-line treatment of non-small cell lung cancer in adult patients who are not candidates for potentially curative surgery and/or radiation therapy.
CELG: 119.57 (+1.10), CELGZ: 3.24 (+0.01)
Amgen's Long Case Strengthens After Kyprolis Data
Investing Healthcare - at Seeking Alpha - Mon Mar 02, 7:41AM CST
AMGN: 159.19 (+0.63), CELG: 119.57 (+1.10)
(0)
(0)Scroll down for more posts ▼